
TABLE OF CONTENTS

PREFACE	xi
INTRODUCTION	xv
1. ORGANIZATION	1
1.0 Executive Management	1
1.2 Quality	5
1.3 Emergency Operation Plans	8
1.4 Operational Continuity	8
1.5 Assessment of Risk	8
1.6 Communication of Concerns	8
1.7 Customer Focus	8
1.8 Human Subjects Research	9
2. RESOURCES	10
2.0 Resources	10
2.1 Human Resources	10
2.2 Access to Ancillary Services and Direct Patient Care	12
3. EQUIPMENT	13
3.0 Equipment	13
3.1 Equipment Specifications	13
3.2 Qualification of Equipment	13
3.3 Use of Equipment	13
3.4 Equipment Monitoring and Maintenance	14
3.5 Equipment Traceability	15
3.6 Information Systems	15

Table of Contents

4. AGREEMENTS 18

4.0 Agreements. 18

4.1 Agreement Review 18

4.2 Changes to Agreements 18

4.3 Agreements Relating to Cellular Therapy Products,
Materials, and Services 18

4.4 Educational and Promotional Materials 21

4.5 Donor Informed Consent 22

4.6 Authorization for Cadaveric Donors 23

4.7 Patient Informed Consent 23

4.8 Obtaining Materials, Services, and Cellular
Therapy Products 24

4.5A Donor Informed Consent or Authorization 26

4.7A Patient Informed Consent 30

5. PROCESS CONTROL 32

5.0 Process Control 32

5.1 General Elements 32

5.2 Process and Procedure Development and
Change 34

5.3 Outcomes Data 36

5.4 Quality Control 37

5.5 Materials Management 38

5.6 Methods and Operational Controls 41

5.7 Product Identification and Traceability 43

5.8 Labels, Labeling, and Labeling Controls 44

5.9 Transport and Shipping 47

5.10 Inspection and Testing of Products 48

5.11 Storage and Preservation 50

5.12 Donor Evaluation 51

5.13 Medical Management and Emergency Care of
Donors 63

5.14 Procurement 64

5.15 Procurement Goals 67

5.16 Packaging 67

5.17	Processing	68
5.18	Storage of Noncryopreserved Products	70
5.19	Cryopreservation	71
5.20	Expiration Dates and Stability of Products	73
5.21	Discard and Disposal	74
5.22	Evaluation to Make a Product Available for Distribution	74
5.23	Distribution	76
5.24	Product Issue	77
5.25	Clinical Program	79
5.26	Clinical Care of the Recipient	79
5.27	Preparation of the Recipient for Administration of Cellular Therapy Products	80
5.28	Receipt and Storage of the Product	80
5.29	Administration	81
5.30	Postadministration Monitoring	84
5.8.2A	Requirements for Labeling of Cellular Therapy Products	85
5.8.2B	Requirements for Labeling Shipping Containers . . .	88
5.9.5A	Labeling and Packaging Requirements Upon Shipping of Cellular Therapy Products	89
5.12A	General Requirements for Cellular Therapy Product Donors.	90
5.12B	Clinical Evaluation and Laboratory Testing of Living Allogeneic Donors	95
5.12C	Clinical Evaluation and Laboratory Testing of Autologous Donors.	98
5.12D	Clinical Evaluation and Laboratory Testing of Mothers of Cord Blood or Gestational Material Donors	99
5.12E	Clinical Evaluation and Laboratory Testing of Cadaveric Donors	101
5.17A	Processing Tests for HPC, Apheresis and HPC, Marrow	103

Table of Contents

- 5.17B Processing Tests for HPC, Cord Blood104
- 5.17C Processing Tests for Cellular Therapy Products
Other than HPC, Apheresis; HPC, Marrow; and
HPC, Cord Blood106
- 6. DOCUMENTS AND RECORDS 108**
 - 6.0 Documents and Records108
 - 6.1 Document Control 108
 - 6.2 Record Control 110
 - 6.3 Electronic Records 113
 - 6.2.1A Retention of Records.....115
- 7. DEVIATIONS, NONCONFORMING PRODUCTS OR
SERVICES, AND ADVERSE EVENTS 128**
 - 7.0 Deviations, Nonconforming Products or
Services, and Adverse Events128
 - 7.1 Deviations 128
 - 7.2 Control of Nonconforming Products or Services .. 129
 - 7.3 Adverse Events 130
 - 7.4 Reporting 131
- 8. INTERNAL AND EXTERNAL ASSESSMENTS 132**
 - 8.0 Internal and External Assessments132
 - 8.1 Internal Assessments 132
 - 8.2 External Assessments 132
 - 8.3 Management of Assessment Results 132
 - 8.4 Monitoring Clinical Activities 132
 - 8.5 Quality Monitoring 133
- 9. PROCESS IMPROVEMENT 134**
 - 9.0 Process Improvement.....134
 - 9.1 Corrective Action 134
 - 9.2 Preventive Action 134
 - 9.3 Performance Improvement 135